Manipal Health IPO Opens Soft as Debt Cleanup Takes Centre Stage

Manipal Health Enterprises opened its ₹9,275 crore IPO on July 29 with just 14% subscribed by mid-afternoon, according to NSE data cited by Upstox. Retail led at 22%, QIBs matched the overall 14%, and non-institutional buyers sat at 6%.

The price band is ₹560-₹590. The issue mixes an ₹8,000 crore fresh issue with a ₹1,275 crore offer for sale. It closes July 31 and targets listing on August 5. The muted open sits against a larger fact: most of the new money is earmarked to clean up debt from a rapid acquisition run that lifted the hospital count and cut profits in the same year.

The ₹9,275 Crore Offer in Plain Numbers

The fresh issue covers 13.56 crore shares. Existing shareholders are selling up to 2.16 crore shares. At the upper band the total haul reaches about ₹9,275 crore. Face value is ₹2. Minimum application is one lot of 25 shares, or ₹14,750 at the top of the band.

Bids covered 1.23 crore shares against 9.01 crore on offer in the public portion. Eligible employees get a reservation of up to ₹15 crore and a ₹56 per-share discount. Anchor investors had already put in ₹4,167 crore before the open, drawing names such as Abu Dhabi Investment Authority, Morgan Stanley Asia, Goldman Sachs Bank Europe, ICICI Prudential MF, Aditya Birla Sun Life MF, UTI MF, Kotak MF and HSBC MF.

The deal sits inside what the site has already flagged as the busiest IPO week of 2026 so far.

Most Fresh Cash Goes Straight to Debt

According to the abridged prospectus objects and financials, the company will use about ₹5,552.76 crore of net fresh proceeds to repay or prepay borrowings and accrued interest at subsidiary Manipal Hospitals Private Limited. Another ₹574 crore funds a further minority stake in step-down subsidiary Sahyadri Hospitals. General corporate purposes take the rest, capped at 25% of gross proceeds.

• Debt repayment: ₹5,552.76 crore (roughly 47% of consolidated borrowings as of late May)
• Sahyadri minority stake: ₹574 crore (third tranche after two earlier purchases)
• General corporate: remainder after expenses, under the 25% ceiling

The Economic Times reported that debt more than doubled in a year. Consolidated borrowings rose to ₹10,553 crore by March 2026 from ₹4,767 crore a year earlier. Net debt including leases climbed to 3.74 times adjusted EBITDA from 2 times. Manipal issued ₹5,310 crore of listed NCDs in September 2025 at a 9.03% coupon to fund Sahyadri tranches; the bonds require mandatory prepayment on listing.

Management has said the IPO should leave the group virtually net debt-free. Interest savings alone are being watched closely by market participants who track the healthcare pack.

Beds and Revenue Climbed, Profit Did Not

Manipal now runs 49 hospitals (including O&M) with 13,037 licensed beds across 14 states and union territories as of March 31, 2026. It is the largest pan-India multispecialty private chain by bed capacity, per the CRISIL material cited in the prospectus. The network served 7.63 million patients in FY26. Key clusters sit in Karnataka, Maharashtra-Goa and eastern states.

Revenue from operations rose to ₹10,335.75 crore in FY26 from ₹8,242 crore in FY25 and ₹6,172 crore in FY24. Profit for the year, however, fell to ₹916.5 crore from ₹1,082 crore a year earlier after a jump from ₹533 crore in FY24. Finance costs surged about 69% to ₹864 crore. Depreciation also rose. Sahyadri added revenue after the October 2025 close but posted a loss in the stub period and dragged consolidated profit.

Acquisitions of AMRI (2023), Medica Synergie (2024) and Sahyadri (2025) drove the bed jump from roughly 9,500 licensed beds in March 2024. The same deals loaded the balance sheet. That is the irony investors are pricing on Day 1: the growth machine created the leverage the IPO must now unwind.

Who Is Selling and Who Anchored

Promoters include Dr. Ranjan Ramdas Pai and Manipal group entities alongside Temasek-linked vehicles (Imperius Healthcare Investments and related Singapore holdings). TPG Capital and other existing investors are among the OFS sellers. The company will receive none of the OFS proceeds.

Anchor demand of ₹4,167 crore brought a mix of sovereign, global banks and domestic mutual funds. That book closed before the public open. Public Day 1 interest has been thinner so far, especially among non-institutional buyers.

Almost ₹5,553 crore from the fresh issue will be used to repay debt… This should add around 350-400 crore on FY27 PAT. This is 40% growth on FY26 PAT, which is only because of lower finance cost.

That line, posted on X by investor Tushar Sarkar (@tsatwork) as the issue opened, captures the mechanical upside many long-only readers are calculating. Secular bed and occupancy growth would sit on top.

Valuation Looks Full and the Grey Market Agrees

At ₹590 the issue prices the company near an $8 billion valuation and roughly 84-85 times FY26 earnings, depending on the exact share count used. Peers such as Apollo Hospitals, Max Healthcare and Fortis trade on hospital-specific multiples that still leave Manipal looking expensive on a trailing basis. Pre-issue book value multiple sits near 8 times in some broker notes circulating on X.

Grey-market premium has slid. Reports on July 28 put GMP near ₹9-13, or about 1.5-2% over the upper band. Earlier chatter had floated higher single-digit percentage premiums. Live X tallies on Day 1 still showed GMP around ₹10. Soft secondary interest matches the slow primary book.

On X, one detailed thread from @abhinavenigma called the stock “fully valued” with “zero margin of safety at ₹590” and advised waiting for post-listing consolidation. Another analyst, @Paryan_Sharma, pushed back that hospitals are judged on post-IPO balance-sheet quality more than raw trailing PE and kept high excitement for institutional demand. The split itself is useful: quality of the franchise is rarely disputed; the entry price is.

1. July 29-31, 2026, Public subscription window
2. August 3, Basis of allotment finalisation
3. August 4, Shares credited to demat
4. August 5, Expected listing on BSE and NSE

Investors watching broader market levels traders watch will also note that large IPOs can absorb liquidity even when the index tone is constructive.

What a Cleaner Balance Sheet Could Unlock

CEO Dilip Jose told reporters the group plans to add roughly 2,400 beds over three to four years, an 18% lift on the current base, with about ₹4,000 crore of capex earmarked. Brownfield and greenfield projects plus selective further acquisitions remain on the table; a non-binding term sheet for another Karnataka hospital was signed in June 2026.

Once the high-coupon NCDs and other acquisition debt are retired, finance costs should drop sharply. That mechanical PAT lift is the near-term story many institutional models already bake in. Longer term, the network’s leadership in Bengaluru, Kolkata and Pune plus scale in cardiac, oncology, ortho and neuro gives it a platform peers must still match bed-for-bed.

Day 1’s 14% take-up and the thin GMP do not kill the franchise. They simply price the IPO as a repair job first and a growth vehicle second. The beds are real. The debt bill is also real. Investors who want the former are being asked to fund the latter at a full multiple. That is the trade on offer until the book closes on July 31.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPOs and equity investments carry market risk; read all offer documents carefully before investing.